Display options
Cite
Green C, Picot J, Loveman E, et al. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics. 2005;23(12):1271-82doi: 10.2165/00019053-200523120-00010.
Green, C., Picot, J., Loveman, E., Takeda, A., Kirby, J., & Clegg, A. (2005). Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. PharmacoEconomics, 23(12), 1271-82. https://doi.org/10.2165/00019053-200523120-00010
Green, Colin, et al. "Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease." PharmacoEconomics vol. 23,12 (2005): 1271-82. doi: https://doi.org/10.2165/00019053-200523120-00010
Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics. 2005;23(12):1271-82. doi: 10.2165/00019053-200523120-00010. PMID: 16336020.
Copy Download .nbib Format: NLM
Share it on

Pharmacoeconomics. 2005;23(12):1271-82. doi: 10.2165/00019053-200523120-00010.

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

PharmacoEconomics

Colin Green, Joanna Picot, Emma Loveman, Andrea Takeda, Jo Kirby, Andrew Clegg

Affiliations

  1. Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development, University of Southampton, Southampton, UK. [email protected]

PMID: 16336020 DOI: 10.2165/00019053-200523120-00010

Abstract

OBJECTIVE: To estimate the cost effectiveness (from the UK NHS and personal social services perspective) of the cholinesterase inhibitors donepezil, rivastigmine and galantamine compared with usual care in the treatment of mild to moderately severe Alzheimer's disease. Patients had a mean age of 74 years, a mean disease duration of 1 year and a mean Alzheimer's disease assessment scale-cognitive subscale score of 24.

METHODS: A pharmacoeconomic model was used to predict long-term outcomes over a 5-year time horizon and to estimate the cost effectiveness of cholinesterase inhibitors for the management of Alzheimer's disease. The model structure is informed by a systematic review of the literature on the clinical and cost effectiveness of cholinesterase inhibitors and a review of the literature on the costs and outcomes associated with treatment for Alzheimer's disease. The main outcome measure used was the cost per quality-adjusted life-year (QALY) gained. All healthcare costs (excluding cholinesterase inhibitor costs) were indexed to pounds sterling (2003 values). Drug costs are 2005 values. Multivariate probabilistic sensitivity analysis and scenario analysis were undertaken to assess uncertainty in the results.

RESULTS: The clinical benefits on cognition from treatment with cholinesterase inhibitors resulted in an incremental cost per QALY gained ranging from 53,780 pounds sterling to 74,735 pounds sterling, over 5 years (vs usual care). Uncertainty analysis suggests that the probability of any of these treatments having an incremental cost per QALY of < 30,000 pounds sterling is < 21%. The key determinants of cost effectiveness were the effectiveness of treatment, the mean treatment cost and the cost savings associated with an expected delay in disease progression.

CONCLUSIONS: Results presented in this paper suggest that the use of cholinesterase inhibitors may not be a cost-effective use of NHS resources. Guidance from the National Institute for Health and Clinical Effectiveness (NICE) in the UK on their judgements surrounding the acceptability of technologies as an effective use of resources, indicates there would need to be special reasons for accepting cholinesterase inhibitors as a cost-effective use of NHS resources.

References

  1. Am J Psychiatry. 2003 Nov;160(11):2003-11 - PubMed
  2. Clin Ther. 1999 Jul;21(7):1230-40 - PubMed
  3. Neurology. 2004 Jul 27;63(2):214-9 - PubMed
  4. Eur J Neurol. 1999 Jul;6(4):423-9 - PubMed
  5. Aging Ment Health. 2001 Feb;5(1):14-22 - PubMed
  6. Dement Geriatr Cogn Disord. 2002;14(2):84-9 - PubMed
  7. Neurology. 2000 Jun 27;54(12):2269-76 - PubMed
  8. Curr Med Res Opin. 2002;18(6):347-54 - PubMed
  9. Lancet. 2004 Jun 26;363(9427):2105-15 - PubMed
  10. Arch Gerontol Geriatr Suppl. 2001;7:151-8 - PubMed
  11. BMJ. 1999 Mar 6;318(7184):633-8 - PubMed
  12. Br J Psychiatry. 2002 Feb;180:120-5 - PubMed
  13. Neurology. 2001 Sep 25;57(6):972-8 - PubMed
  14. Stat Med. 2000 Jun 15-30;19(11-12):1607-16 - PubMed
  15. Int J Geriatr Psychiatry. 2003 Aug;18(8):740-7 - PubMed
  16. Int J Geriatr Psychiatry. 1998 Jul;13(7):445-53 - PubMed
  17. Neurology. 2001 Aug 14;57(3):481-8 - PubMed
  18. Neurology. 1998 Jan;50(1):136-45 - PubMed
  19. Neurology. 2001 Sep 25;57(6):964-71 - PubMed
  20. Clin Ther. 2003 Jun;25(6):1806-25 - PubMed
  21. Arch Neurol. 2000 Jan;57(1):94-9 - PubMed
  22. Pharmacoeconomics. 2002;20(9):629-37 - PubMed
  23. Clin Ther. 2000 Apr;22(4):439-51 - PubMed
  24. BMJ. 2000 Dec 9;321(7274):1445-9 - PubMed
  25. Int J Geriatr Psychiatry. 2001 Sep;16(9):852-7 - PubMed
  26. Neurology. 2001 Sep 25;57(6):957-64 - PubMed
  27. Lancet. 1999 Oct 30;354(9189):1527-8 - PubMed
  28. Cochrane Database Syst Rev. 2001;(4):CD001747 - PubMed
  29. JAMA. 1997 Mar 12;277(10):806-12 - PubMed
  30. J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):589-95 - PubMed
  31. Dementia. 1996 Nov-Dec;7(6):293-303 - PubMed
  32. J Am Geriatr Soc. 1999 May;47(5):570-8 - PubMed
  33. Arch Neurol. 1987 Nov;44(11):1122-6 - PubMed
  34. Neurology. 1999 Apr 12;52(6):1138-45 - PubMed
  35. Int J Clin Pract. 2002 Jul-Aug;56(6):441-6 - PubMed
  36. Arch Neurol. 2003 Feb;60(2):253-9 - PubMed
  37. Dement Geriatr Cogn Disord. 2000 Nov-Dec;11(6):299-313 - PubMed
  38. J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):343-4 - PubMed
  39. Health Trends. 1993;25(1):31-7 - PubMed
  40. Med Care. 1996 Jul;34(7):702-22 - PubMed
  41. Neurology. 2001 Aug 14;57(3):489-95 - PubMed
  42. Neurology. 2003 Nov 25;61(10):1356-61 - PubMed
  43. J Int Med Res. 2004 Mar-Apr;32(2):149-59 - PubMed
  44. Med Decis Making. 2000 Oct-Dec;20(4):413-22 - PubMed
  45. J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):310-4 - PubMed
  46. Dement Geriatr Cogn Disord. 2003;15(1):44-54 - PubMed
  47. Arch Intern Med. 1998 May 11;158(9):1021-31 - PubMed
  48. Dement Geriatr Cogn Disord. 1999 May-Jun;10(3):237-44 - PubMed
  49. Int J Geriatr Psychiatry. 2004 Jan;19(1):58-67 - PubMed
  50. Neurology. 2000 Jun 27;54(12):2261-8 - PubMed
  51. Dement Geriatr Cogn Disord. 2002;13(1):33-9 - PubMed
  52. Pharmacoeconomics. 2000 Apr;17(4):351-60 - PubMed
  53. Br J Psychiatry. 2002 Jul;181:36-42 - PubMed
  54. Int J Geriatr Psychiatry. 2000 Mar;15(3):208-18 - PubMed
  55. J Am Geriatr Soc. 1992 Sep;40(9):922-35 - PubMed

Substances

MeSH terms

Publication Types